Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last2,641 to 2,660 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study | 94 of 1,396 83 of 1,403 | 0.8 points -1.0 to 2.6 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations Occurring in a Year | 947 of 1,396 977 of 1,403 | -1.8 points -5.2 to 1.6 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to the Addition of a Further COPD Controller Medication Occurring in a Year | 72 of 1,396 142 of 1,403 | -5.0 points -6.9 to -3.0 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Severe Exacerbations Occurring in a Year | 122 of 1,396 97 of 1,403 | 1.8 points -0.2 to 3.8 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Drug Reactions | 23 of 1,396 10 of 1,403 | 0.9 points 0.1 to 1.8 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events | 404 of 1,396 383 of 1,403 | 1.6 points -1.7 to 5.0 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Fatal Serious Adverse Events of Pneumonia | 13 of 1,396 13 of 1,403 | 0.0 points -0.8 to 0.8 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| FF/VI 100 mcg/25 mcg vs Usual Care: serious adverse events | 404 of 1,396 383 of 1,403 | 1.6 points -1.7 to 5.0 | 2,799 | NCT01551758 A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD) |
| Investigational Vaccine vs Control Group: serious adverse events | 257 of 1,399 258 of 1,396 | -0.1 points -3.0 to 2.8 | 2,795 | NCT00953927 A Study of MVA85A in Healthy Infants |
| Intensive Blood-Pressure Lowering vs Guideline-Recommended Blood-Pressure Lowering: A Composite of Death or Dependency, With Dependency Being Defined by a Score of 3 to 5 on the Modified Rankin Scale (mRS) | 719 of 1,382 785 of 1,412 | -3.6 points -7.3 to 0.1 | 2,794 | NCT00716079 The Second Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial |
| Investigational Vaccine vs Control Group: To Evaluate the QuantiFERON Conversion Rate at Final Study Assessment in MVA85A/AERAS-485 Recipients Compared to Controls in Infants Without a Diagnosis of Tuberculosis During the Trial. | 178 of 1,398 171 of 1,394 | 0.5 points -2.0 to 2.9 | 2,792 | NCT00953927 A Study of MVA85A in Healthy Infants |
| V419 Lots A, B, and C Combined vs Control: serious adverse events | 94 of 2,390 15 of 397 | 0.2 points -2.3 to 1.9 | 2,787 | NCT01340937 A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) |
| Intervention Group vs Control Group: Number of Patients With Abnormal Laboratory Results Received and Recognized by Provider | 1,339 of 1,426 1,292 of 1,357 | -1.3 points -3.0 to 0.4 | 2,783 | NCT02798354 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE) |
| Intervention Group vs Control Group: Number of Patients With Abnormal Laboratory Results With Appropriate Actions Without Delay | 1,329 of 1,426 1,273 of 1,357 | -0.6 points -2.5 to 1.2 | 2,783 | NCT02798354 Reducing Diagnostic Errors in Primary Care Pediatrics (Project RedDE) |
| Nintedanib Initiators Cohort vs Pirfenidone Initiators Cohort: Number of Patients With Dose Reduction and/or Temporary Dose Reduction (Sub-optimal Dose) by 12 Months | 301 of 1,389 373 of 1,389 | -5.2 points -8.4 to -2.0 | 2,778 | NCT05779007 Dose Reduction and Discontinuation With Anti-Fibrotic Medications |
| Group 1: MenACYW Conjugate Vaccine vs MENVEO®: Number of Participants With Medically Attended Adverse Event (MAAEs) | 1,581 of 2,080 526 of 697 | 0.5 points -3.0 to 4.3 | 2,777 | NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) | 7 of 2,080 2 of 697 | 0.0 points -0.7 to 0.5 | 2,777 | NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: deaths from any cause | 3 of 2,080 0 of 697 | 0.1 points -0.4 to 0.4 | 2,777 | NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: Number of Participants With Unsolicited Adverse Events | 1,352 of 2,080 437 of 697 | 2.3 points -1.8 to 6.5 | 2,777 | NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
| Group 1: MenACYW Conjugate Vaccine vs Group 2: MENVEO®: serious adverse events | 108 of 2,080 21 of 697 | 2.2 points 0.4 to 3.6 | 2,777 | NCT03673462 Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers |
Code
curl "https://conductscience.org/api/comparisons/v1?page=133"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=133
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01551758-8119a972",
"title": "FF/VI 100 mcg/25 mcg vs Usual Care: Number of Participants With Serious Adverse Events (SAEs) of Pneumonia During the Study",
"summary": "94 of 1396 against 83 of 1403; risk difference 0.8 points, 95% interval -1.0 to 2.6; NCT01551758, A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",
"record": "/library/comparisons/NCT01551758-8119a972",
"nct_id": "NCT01551758",
"kind": "outcome",
"participants": 2799,
"risk_difference": {
"value": 0.008176298435403469,
"lower": -0.009949845672234989,
"upper": 0.02638393685750703
},
"group_1": "94 of 1,396",
"group_2": "83 of 1,403",
"difference": "0.8 points",
"interval": "-1.0 to 2.6",
"trial_title": "A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)"
},
{
"id": "NCT01551758-c8ea559f",
"title": "FF/VI 100 mcg/25 mcg vs Usual Care: Time to First Moderate/Severe Exacerbations Occurring in a Year",
"summary": "947 of 1396 against 977 of 1403; risk difference -1.8 points, 95% interval -5.2 to 1.6; NCT01551758, A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)",
"record": "/library/comparisons/NCT01551758-c8ea559f",
"nct_id": "NCT01551758",
"kind": "outcome",
"participants": 2799,
"risk_difference": {
"value": -0.017998170110303913,
"lower": -0.05228135682213559,
"upper": 0.01633790053643234
},
"group_1": "947 of 1,396",
"group_2": "977 of 1,403",
"difference": "-1.8 points",
"interval": "-5.2 to 1.6",
"trial_title": "A Randomised Effectiveness Study Comparing Fluticasone Furoate (FF, GW685698)/Vilanterol (VI, GW642444) With Standard Treatment in Chronic Obstructive Pulmonary Disease (COPD)"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=134",
"request_id": "fQU1YI7KJbPJ2LqF"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant